SELLAS Life Sciences Group Announces Initial Topline Phase 2a Data Of SLS009 In Acute Myeloid Leukemia
Portfolio Pulse from Benzinga Newsdesk
SELLAS Life Sciences Group has announced initial topline Phase 2a data for SLS009 in Acute Myeloid Leukemia (AML). SLS009 is the first CDK9 inhibitor in combination with AZA/VEN to achieve a complete response in an AML patient resistant to Venetoclax combination therapies. The first patient enrolled achieved CR and is in the fifth month of treatment. Four patients continue on treatment and all patients are alive. Anti-leukemic effects were observed in all patients and no significant safety issues were observed.
October 16, 2023 | 12:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SELLAS Life Sciences' SLS009 has shown promising results in Phase 2a trials for Acute Myeloid Leukemia. This could potentially boost the company's stock in the short term.
The positive initial results from the Phase 2a trials of SLS009, a drug developed by SELLAS Life Sciences, could potentially increase investor confidence in the company. This could lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100